Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JK08 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Salubris Biotherapeutics Inc
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
JK08 + pembrolizumab is an experimental combination therapy comprised of JK08—a recombinant fusion protein that contains a CTLA-4-specific antibody and an IL-15 fusion domain—and pembrolizumab, a humanized monoclonal anti-PD-1 antibody. JK08 is designed to deplete regulatory T cells and reverse immunosuppression in the tumor microenvironment via CTLA-4 targeting and stimulate natural killer (NK) cell expansion and ADCC (antibody-dependent cellular cytotoxicity) via the IL-15 domain. Pembrolizumab blocks the PD-1 receptor on T-cells, enabling antitumor immune responses. This combination is being clinically investigated in patients with advanced, unresectable, or metastatic cancers, aiming to leverage potentially synergistic immunomodulatory effects for improved clinical outcomes[1][2].
- Other names
- pembrolizumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)IL15RA (Interleukin-15 receptor subunit alpha)
Beyond the preview
Go deeper on JK08 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JK08 + pembrolizumab.